Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Operating Leases (2022 - 2025)

Rani Therapeutics Holdings (RANI) has 4 years of Operating Leases data on record, last reported at $3.0 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 26.11% year-over-year to $3.0 million; the TTM value through Sep 2025 reached $3.0 million, down 26.11%, while the annual FY2024 figure was $3.6 million, N/A changed from the prior year.
  • Operating Leases reached $3.0 million in Q3 2025 per RANI's latest filing, down from $3.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.7 million in Q1 2024 and bottomed at $59000.0 in Q4 2022.
  • Average Operating Leases over 4 years is $2.2 million, with a median of $3.0 million recorded in 2025.
  • Peak YoY movement for Operating Leases: tumbled 46.23% in 2023, then soared 2249.12% in 2024.
  • A 4-year view of Operating Leases shows it stood at $59000.0 in 2022, then soared by 189.83% to $171000.0 in 2023, then skyrocketed by 2026.9% to $3.6 million in 2024, then dropped by 18.39% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $3.0 million in Q3 2025, $3.2 million in Q2 2025, and $3.4 million in Q1 2025.